REGULATION OF ENGINEERED EXTRACELLULAR VESICLE THERAPIES

1. INTRODUCTION

Extracellular vesicles (EVs) are membrane-bound particles released by cells that transport proteins, lipids, and nucleic acids. Engineered EV therapies modify these vesicles or their source cells to deliver therapeutic cargo, target specific tissues, or influence biological processes. Potential applications include cancer treatment, regenerative medicine, inflammation management, and targeted drug delivery.

Their regulation must address product quality, biological safety, manufacturing consistency, clinical evidence, informed consent, and long-term monitoring. Because engineered EVs may have complex biological effects, developers cannot assume that naturally occurring vesicles or cell-derived materials are automatically safe for therapeutic use.

2. LEGAL FRAMEWORK IN INDIA

A. DRUGS AND COSMETICS ACT, 1940, AND NEW DRUGS AND CLINICAL TRIALS RULES, 2019

Therapeutic EV products may fall within the applicable framework for new drugs and biological products, depending on their characteristics and intended use. Clinical trials require applicable regulatory permission and ethics committee approval. Manufacturing and marketing must comply with the relevant licensing and quality requirements.

The Central Drugs Standard Control Organization (CDSCO) and the Drugs Controller General of India (DCGI) perform relevant regulatory functions. India's existing framework must be applied to each product because there is no single dedicated statutory pathway covering every EV therapy. <Cite refs={["turn163908search1","turn163908search2"]}/>

B. BIOSAFETY AND MANUFACTURING QUALITY

Where genetic engineering or modified producer cells are involved, the applicable biosafety requirements must be assessed. Manufacturers should establish validated procedures for source-cell qualification, EV isolation, purification, potency testing, sterility, identity, stability, and contamination control.

C. INFORMED CONSENT AND PATIENT SAFETY

Clinical investigations must comply with applicable consent and participant-protection requirements. Consent documents should explain the experimental nature of the treatment, known risks, uncertainties, alternatives, and procedures for reporting adverse events.

3. PRINCIPAL REGULATORY REQUIREMENTS

A. PRODUCT CHARACTERISATION: Developers should establish vesicle identity, size distribution, composition, cargo, purity, and biological activity.

B. PRECLINICAL EVALUATION: Studies should examine toxicity, biodistribution, immune responses, unintended biological effects, and risks associated with the therapeutic cargo.

C. CLINICAL TRIAL AUTHORISATION: Human studies must obtain the permissions and ethics approvals required by the applicable legal framework.

D. POST-MARKET SURVEILLANCE: Approved products require appropriate safety monitoring, adverse-event reporting, and investigation of manufacturing deviations.

E. RESPONSIBLE COMMERCIALISATION: Experimental EV therapies should not be promoted as proven treatments without adequate evidence and the necessary authorisations.

4. RELEVANT CASE LAWS

1. SWASTHYA ADHIKAR MANCH v. UNION OF INDIA (2013–2014) — DIRECT CLINICAL-TRIAL AUTHORITY

The Supreme Court considered concerns regarding clinical-trial regulation and participant protection in India.

Application: EV clinical trials require meaningful oversight, appropriate safeguards, and compliance with regulatory requirements. The case is relevant to experimental therapies but does not specifically concern extracellular vesicles.

2. SAMIRA KOHLI v. DR. PRABHA MANCHANDA (2008) — DIRECT CONSENT PRINCIPLE

The Supreme Court explained the requirements of valid informed consent in medical treatment.

Application: Patients participating in experimental EV therapy must receive adequate information and provide legally valid consent. A signed form alone does not cure inadequate disclosure.

3. JUSTICE K.S. PUTTASWAMY (RETD.) v. UNION OF INDIA (2017) — CONSTITUTIONAL PRIVACY AUTHORITY

The Supreme Court recognised privacy as a fundamental right under Article 21.

Application: EV research involving identifiable medical records, genetic information, or sensitive biological data must respect applicable privacy protections and lawful data-processing requirements.

4. VELLORE CITIZENS' WELFARE FORUM v. UNION OF INDIA (1996) — ANALOGOUS PRECAUTIONARY AUTHORITY

The Supreme Court recognised the precautionary principle and polluter-pays principle in Indian environmental law.

Application: Where EV manufacturing or genetically modified producer cells create environmental risks, preventive safeguards and appropriate containment measures are important.

5. INDIAN COUNCIL FOR ENVIRO-LEGAL ACTION v. UNION OF INDIA (1996) — ANALOGOUS LIABILITY AUTHORITY

The Supreme Court applied the polluter-pays principle in addressing industrial environmental contamination.

Application: Where an EV manufacturing operation causes legally attributable environmental damage, applicable law may require remediation and compensation.

6. JACOB MATHEW v. STATE OF PUNJAB (2005) — ANALOGOUS NEGLIGENCE AUTHORITY

The Supreme Court examined the standard for criminal negligence in medical practice.

Application: Allegations involving unsafe EV administration or negligent clinical conduct must be evaluated under the relevant legal standards and evidence. Experimental status does not automatically exempt providers from liability.

5. COMPLIANCE CHALLENGES

Important challenges include inconsistent EV characterisation methods, batch variability, uncertain biodistribution, immune reactions, unintended cargo effects, and limited long-term clinical evidence. Engineered vesicles may also differ substantially according to their source cells and manufacturing processes.

Companies should maintain traceable production records, validated analytical methods, independent quality review, documented adverse-event procedures, and clear allocation of responsibility among manufacturers, sponsors, investigators, and healthcare providers.

6. CONCLUSION

Regulation of engineered extracellular vesicle therapies requires a risk-based approach combining pharmaceutical regulation, biosafety, manufacturing quality, clinical-trial oversight, informed consent, and post-treatment surveillance. Indian legislation provides relevant regulatory mechanisms, although a dedicated comprehensive EV-specific statutory framework has not been established.

The cited judgments provide important principles concerning clinical-trial safeguards, consent, privacy, precaution, and liability. None directly determines the legal status of engineered EV therapies. Effective regulation must therefore apply existing legal requirements carefully to each product while ensuring that scientific innovation does not compromise patient safety or accountability.